Causes and consequences of lipoprotein(a) abnormalities in kidney disease
- PMID: 24129557
- DOI: 10.1007/s10157-013-0875-8
Causes and consequences of lipoprotein(a) abnormalities in kidney disease
Abstract
Lipoprotein(a) is one of the strongest genetically determined risk factors for cardiovascular disease, and patients with chronic kidney disease have major disturbances in lipoprotein(a) metabolism. Concentrations are increased and are influenced by glomerular filtration rate (GFR) and the amount of proteinuria. The reason for this elevation can be increased synthesis, as is the case for patients with nephrotic syndrome or those treated by peritoneal dialysis. In hemodialysis patients, a catabolic block is the reason for this elevation. The elevated concentrations might contribute to the tremendous cardiovascular risk in this particular population. In particular, the genetically determined small apolipoprotein(a) isoforms are associated with an increased risk for cardiovascular events and total mortality.
Similar articles
-
Lipoprotein(a) serum levels and apolipoprotein(a) phenotypes in children with chronic renal disease.Pediatr Res. 1993 Dec;34(6):772-6. doi: 10.1203/00006450-199312000-00015. Pediatr Res. 1993. PMID: 8108191
-
Lipoprotein(a) in renal disease.Am J Kidney Dis. 1996 Jan;27(1):1-25. doi: 10.1016/s0272-6386(96)90026-8. Am J Kidney Dis. 1996. PMID: 8546123 Review.
-
Insulin resistance underlies the elevated cardiovascular risk associated with kidney disease and glomerular hyperfiltration.Rev Cardiovasc Med. 2020 Mar 30;21(1):41-56. doi: 10.31083/j.rcm.2020.01.5102. Rev Cardiovasc Med. 2020. PMID: 32259903 Review.
-
Serum lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in hemodialysis, chronic ambulatory peritoneal dialysis and post-transplant patients.Ren Fail. 2002 Mar;24(2):187-95. doi: 10.1081/jdi-120004095. Ren Fail. 2002. PMID: 12071592
-
Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study.Nephrol Dial Transplant. 2016 Nov;31(11):1901-1908. doi: 10.1093/ndt/gfv428. Epub 2016 Jan 10. Nephrol Dial Transplant. 2016. PMID: 26754832 Clinical Trial.
Cited by
-
Predictive value of procalcitonin in chronic allograft dysfunction in kidney transplant recipients.Exp Ther Med. 2019 Dec;18(6):4603-4608. doi: 10.3892/etm.2019.8113. Epub 2019 Oct 21. Exp Ther Med. 2019. PMID: 31777558 Free PMC article.
-
Initial decrease in the lipoprotein(a) level is a novel prognostic biomarker in patients with acute coronary syndrome.World J Cardiol. 2024 Jun 26;16(6):329-338. doi: 10.4330/wjc.v16.i6.329. World J Cardiol. 2024. PMID: 38993583 Free PMC article.
-
Association between Lipoprotein(a) and diabetic nephropathy in patients with type 2 diabetes.Front Endocrinol (Lausanne). 2024 Jan 15;14:1337469. doi: 10.3389/fendo.2023.1337469. eCollection 2023. Front Endocrinol (Lausanne). 2024. PMID: 38288472 Free PMC article.
-
A comprehensive review on apolipoproteins as nontraditional cardiovascular risk factors in end-stage renal disease: current evidence and perspectives.Int Urol Nephrol. 2019 Jul;51(7):1173-1189. doi: 10.1007/s11255-019-02170-w. Epub 2019 May 22. Int Urol Nephrol. 2019. PMID: 31119518 Review.
-
Genetics of Lipoprotein(a): Cardiovascular Disease and Future Therapy.Curr Atheroscler Rep. 2021 Jun 20;23(8):46. doi: 10.1007/s11883-021-00937-0. Curr Atheroscler Rep. 2021. PMID: 34148150 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources